DocStoX is a free AI-powered research platform for Indian equity markets, covering 5,700+ NSE & BSE stocks with prices, fundamentals, 326 financial ratios, shareholding, FII/DII flows, F&O, IPOs, a visual screener and AI stock scoring.

Yes. DocStoX has a free tier covering stock research, the screener, FII/DII data and educational guides, plus a free MCP API tier (50 tool calls/day) for AI assistants. A Pro plan adds higher limits and advanced features.

What data does DocStoX cover?

Every NSE & BSE listed stock (5,700+ instruments): EOD and intraday prices, income statement / balance sheet / cash flow, 326 ratios, quarterly shareholding, promoter pledge, mutual-fund holdings, FII/DII flows, F&O and option-chain data, analyst forecasts, IPOs, corporate actions and news.

Can AI assistants like ChatGPT or Claude use DocStoX data?

Yes. DocStoX runs a public Model Context Protocol (MCP) server at https://mcp.docstox.com/mcp with 84 tools, so Claude, ChatGPT, Cursor and other MCP clients can pull Indian market data directly. Setup and a free key are at https://docstox.com/mcp.

Positive impactCompany

Aurobindo Pharma arm Acrotech Biopharma launches ADQUEY in US dermatology market

CNBC-TV18 1 hr ago·30 Sept 2026, 4:56 pm

Aurobindo Pharma’s US subsidiary, Acrotech Biopharma, has introduced ADQUEY, a new treatment for a common skin condition. This launch marks a significant step for the company in the competitive dermatology sector.

For investors, this move is a positive development. It shows the company is actively expanding its portfolio in the US market, a key region for growth. Such new product launches can drive revenue and strengthen the company's position against competitors.

Investors should now watch the market reception of ADQUEY. Tracking sales figures and market share will be crucial to understanding the long-term impact of this launch on the company's financial performance.

Affected stocks

Bullish1 stock

Aurobindo Pharma

AUROPHARMA Bullish

₹1,672.00

Bull / bear label is derived from the article's AI sentiment — indicative, not advice. Prices may be delayed.

Key takeaways

Concerns Aurobindo Pharma (AUROPHARMA).
Category: Company.
AI reads the tone as positive (potentially bullish) for the stock.
Assessed as a significant, market-relevant update.

Why it matters

A meaningful update for Aurobindo Pharma worth tracking. The tone is positive — historically associated with upward pressure, though not predictive. Use the price and stock snapshot to gauge how the market is responding.

Summary & analysis by DocStoX. Full story at CNBC-TV18.